251 results on '"Di Bona D"'
Search Results
2. Experimental and analytical procedure for the characterization of innovative working fluids for power plants applications
- Author
-
Di Marcoberardino, G., Invernizzi, C.M., Iora, P., Ayub, A., Di Bona, D., Chiesa, P., Binotti, M., and Manzolini, G.
- Published
- 2020
- Full Text
- View/download PDF
3. Experimental characterisation of CO2 + C6F6 mixture: Thermal stability and vapour liquid equilibrium test for its application in transcritical power cycle
- Author
-
Di Marcoberardino, G., primary, Morosini, E., additional, Di Bona, D., additional, Chiesa, P., additional, Invernizzi, C., additional, Iora, P., additional, and Manzolini, G., additional
- Published
- 2022
- Full Text
- View/download PDF
4. As-needed anti-inflammatory reliever therapy for asthma management: evidence and practical considerations
- Author
-
Bianco A., Contoli M., Di Marco F., Saverio Mennini F., Papi A., Ando F., Antonicelli L., Battaglia S., Beghe B., Braido F., Caminati M., Costantino M. T., D'Amato M., Dente F., Di Bona D., Facciolongo N., Fois A., Graziani E., Pelaia G., Poto S., Radovanovic D., Rumi G., Savi E., Schino P., Solidoro P., Bianco A., Contoli M., Di Marco F., Saverio Mennini F., Papi A., Ando F., Antonicelli L., Battaglia S., Beghe B., Braido F., Caminati M., Costantino M.T., D'Amato M., Dente F., Di Bona D., Facciolongo N., Fois A., Graziani E., Pelaia G., Poto S., Radovanovic D., Rumi G., Savi E., Schino P., Solidoro P., Bianco, A., Contoli, M., Di Marco, F., Saverio Mennini, F., Papi, A., Ando, F., Antonicelli, L., Battaglia, S., Beghe, B., Braido, F., Caminati, M., Costantino, M. T., D'Amato, M., Dente, F., Di Bona, D., Facciolongo, N., Fois, A., Graziani, E., Pelaia, G., Poto, S., Radovanovic, D., Rumi, G., Savi, E., Schino, P., and Solidoro, P.
- Subjects
0301 basic medicine ,Budesonide ,medicine.medical_specialty ,Immunology ,Settore SECS-P/03 ,Anti-Inflammatory Agents ,Socio-culturale ,Disease ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Asthma management ,asthma ,pharmacology and pharmacogenomics ,pneumology ,03 medical and health sciences ,0302 clinical medicine ,Symptom relief ,Maintenance therapy ,medicine ,Immunology and Allergy ,Humans ,Anti-Asthmatic Agents ,Pneumology ,Intensive care medicine ,Asthma ,Asthma, Pharmacology and pharmacogenomics, Pneumology ,business.industry ,Inhaler ,Pharmacology and pharmacogenomics ,Respiratory disease ,pharmacology and pharmacogenomic ,medicine.disease ,respiratory tract diseases ,Bronchodilator Agents ,030104 developmental biology ,030228 respiratory system ,business ,medicine.drug - Abstract
Asthma is a chronic respiratory disease in which airway inflammation is a key feature, even in the milder expressions of the disease. The conventional pharmacological approach to mild asthma has long relied on reliever therapy with as-needed short-acting beta-agonists (SABAs), while anti-inflammatory maintenance with inhaled corticosteroids (ICSs) has been reserved for patients with more persistent asthma. Poor adherence to maintenance treatment is an important issue in asthma management, and can partly explain suboptimal symptom control. Over-reliance on SABA bronchodilators for rapid symptom relief is common in real life and potentially leads to an increased risk of asthma morbidity and mortality. Combined anti-inflammatory and reliever medications in a single inhaler have the potential to overcome these limitations. Recent studies in patients with mild asthma have shown that anti-inflammatory reliever therapy with budesonide-formoterol, given on an as-needed basis, is superior to SABA in ensuring asthma control and non-inferior to budesonide maintenance therapy in preventing exacerbations. To address the implications of these important findings for the management of patients with asthma, Italian specialists convened at a series of meetings held during the second half of 2018 across Italy. This article presents their position on these topics and includes a review of the evidence supporting the use of anti-inflammatory reliever therapy in mild asthma and the implementation of this novel approach in clinical practice.
- Published
- 2021
5. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
- Author
-
Nettis, E, primary, Ferrucci, SM, additional, Ortoncelli, M, additional, Pellacani, G, additional, Foti, C, additional, Di Leo, E, additional, Patruno, C, additional, Rongioletti, F, additional, Argenziano, G, additional, Macchia, L, additional, Tavecchio, S, additional, Napolitano, M, additional, Ribero, S, additional, Bonzano, L, additional, Romita, P, additional, Di Bona, D, additional, Nisticò, SP, additional, Piras, V, additional, Calabrese, G, additional, Detoraki, C, additional, Carbonara, M, additional, and Fabbrocini, G, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response
- Author
-
Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, Detoraki, A, Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, and Detoraki, A
- Subjects
medicine.medical_specialty ,business.industry ,Treatment outcome ,MEDLINE ,Eczema ,Patient characteristics ,Dermatology ,Atopic dermatitis ,medicine.disease ,Antibodies, Monoclonal, Humanized ,Dupilumab ,Severity of Illness Index ,Dermatitis, Atopic ,Infectious Diseases ,Treatment Outcome ,Medicine ,Humans ,business ,Human - Abstract
Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified.
- Published
- 2021
7. KIR2DL3 and the KIR ligand groups HLA‐A‐Bw4 and HLA‐C2 predict the outcome of hepatitis B virus infection
- Author
-
Di Bona, D., Aiello, A., Colomba, C., Bilancia, M., Accardi, G., Rubino, R., Giannitrapani, L., Tuttolomondo, A., Cascio, A., Caiaffa, M. F., Rizzo, S., Di Lorenzo, G., Candore, G., Duro, G., Macchia, L., Montalto, G., and Caruso, C.
- Published
- 2017
- Full Text
- View/download PDF
8. Investigations on the behaviour of 2 kW natural gas fuel processor
- Author
-
Di Bona, D., Jannelli, Elio, Minutillo, M., and Perna, A.
- Published
- 2011
- Full Text
- View/download PDF
9. Modelling and performance analysis of an integrated plasma gasification combined cycle (IPGCC) power plant
- Author
-
Minutillo, M., Perna, A., and Di Bona, D.
- Published
- 2009
- Full Text
- View/download PDF
10. Experimental Characterisation of Co2 + C6f6 Mixture: Thermal Stability and Vapour Liquid Equilibrium Test for its Application in Transcritical Power Cycle
- Author
-
Di Marcoberardino, G., Morosini, E., Di Bona, D., Chiesa, P., Invernizzi, C., Iora, P., and Manzolini, G.
- Subjects
CO2-blends ,Transcritical cycle ,History ,Polymers and Plastics ,Vapour liquid equilibrium ,Power cycle performance ,Energy Engineering and Power Technology ,Hexafluorobenzene ,Thermal stability ,Business and International Management ,Industrial and Manufacturing Engineering ,CO2-blends, Vapour liquid equilibrium, Thermal stability, Hexafluorobenzene, Transcritical cycle, Power cycle performance - Published
- 2021
11. A Multicenter Study on the Prevalence of Clinical Patterns and Clinical Phenotypes in Adult Atopic Dermatitis
- Author
-
Nettis, E, primary, Ortoncelli, M, additional, Pellacani, G, additional, Foti, C, additional, Di Leo, E, additional, Patruno, C, additional, Rongioletti, F, additional, Argenziano, G, additional, Ferrucci, SM, additional, Macchia, L, additional, Napolitano, M, additional, Ribero, S, additional, Bonzano, L, additional, Romita, P, additional, Di Bona, D, additional, Bennardo, L, additional, Piras, V, additional, Calabrese, G, additional, Tavecchio, S, additional, Detoraki, C, additional, Carbonara, M, additional, and Fabbrocini, G, additional
- Published
- 2020
- Full Text
- View/download PDF
12. Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
- Author
-
Nettis, E., primary, Fabbrocini, G., additional, Ortoncelli, M., additional, Pellacani, G., additional, Argenziano, G., additional, Di Leo, E., additional, Patruno, C., additional, Stingeni, L., additional, Foti, C., additional, Rongioletti, F., additional, Macchia, L., additional, Tavecchio, S., additional, Napolitano, M., additional, Ribero, S., additional, Bonzano, L., additional, Calabrese, G., additional, Di Bona, D., additional, Nisticò, S.P., additional, Hansel, K., additional, Romita, P., additional, Piras, V., additional, Carbonara, M., additional, Detoraki, A., additional, and Ferrucci, S.M., additional
- Published
- 2020
- Full Text
- View/download PDF
13. Preoperative Chemoradiotherapy of oesophageal cancer: A Systematic Review and Meta-analysis
- Author
-
Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L, and Venturi, A.
- Subjects
Chemotherapy -- Usage ,Chemotherapy -- Health aspects ,Chemotherapy -- Research ,Esophageal cancer -- Care and treatment ,Esophageal cancer -- Health aspects ,Cancer -- Chemotherapy ,Cancer -- Usage ,Cancer -- Health aspects ,Cancer -- Research ,Health - Published
- 2004
14. Increased expression of IL-19 in the epithelium of patients with chronic rhinosinusitis and nasal polyps
- Author
-
Pace, E., Scafidi, V., Di Bona, D., Siena, L., Chiappara, G., Ferraro, M., La Grutta, S., Gallina, S., Speciale, R., Ballacchino, A., Bachert, C., Bousquet, J., and Gjomarkaj, M.
- Published
- 2012
- Full Text
- View/download PDF
15. Assessing the potential of molten carbonate fuel cell-based schemes for carbon capture in natural gas-fired combined cycle power plants
- Author
-
Spinelli, M., primary, Di Bona, D., additional, Gatti, M., additional, Martelli, E., additional, Viganò, F., additional, and Consonni, S., additional
- Published
- 2020
- Full Text
- View/download PDF
16. Quality-related variables at hepatological websites
- Author
-
Fraquelli, M, Conte, D, Cammà, C, Casazza, G, Di Bona, D, Rebulla, P, and Prati, D
- Published
- 2004
- Full Text
- View/download PDF
17. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis
- Author
-
Fiorica, F, Di Bona, D, Schepis, F, Licata, A, Shahied, L, Venturi, A, Falchi, A M, Craxì, A, and Cammà, C
- Published
- 2004
18. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis
- Author
-
DI LORENZO, Gabriele, LETO BARONE, Maria Stefania, LA PIANA, Simona, PLAIA, Antonella, Di Bona, D., DI LORENZO, G., LETO BARONE, M., LA PIANA, S., Plaia, A., and Di Bona, D.
- Subjects
allergic rhinitis ,Pyroglyphidae ,new allergen sensitization ,asthma ,meta-analysi ,Desensitization, Immunologic ,Anti-Allergic Agents ,allergen immunotherapy ,Hypersensitivity ,Animals ,Humans ,Immunization ,Antigens, Dermatophagoides ,Child ,Randomized Controlled Trials as Topic - Abstract
Background Although the preventive efficacy of allergen immunotherapy (AIT) in the onset of new allergen sensitizations has been asserted by many reviews, position papers, and consensus conferences, the evidence available is from only 3 studies. The objective of this work was a systematic review to evaluate the preventive efficacy of AIT in the onset of new allergen sensitizations. The end-point was the risk difference (RD) in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. Methods Computerized bibliographic searches of MEDLINE, EMBASE, and the Cochrane Library (until November 30th, 2016) were done. Random-effects and fixed-effects model meta-analyses were performed. Randomized controlled trials or observational studies comparing children treated with AIT with house dust mite (HDM) to subjects who did not receive AIT, with a long-term observation period (at least 3 years including treatment and follow-up) have been included. Results Eight studies totaling 721 children (390 treated with AIT and 331 with pharmacotherapy) met the inclusion criteria. The risk of bias was high. Low evidence supports the conclusion that AIT prevents the onset of new allergen sensitizations, with 3 of 8 studies reporting a reduction in the onset of new sensitizations in patients treated with AIT vs pharmacotherapy. Our meta-analysis found no difference between AIT and pharmacotherapy, with high heterogeneity (RD, −0.10; 95% confidence interval [CI], −0.31 to 0.11; p = 0.32; I2 = 91.4%). Conclusion The data of this systematic review do not support a preventive effect in the onset of new allergen sensitizations, in children treated with AIT in comparison with those treated with pharmacotherapy.
- Published
- 2017
19. Association of Klotho Polymorphisms with Healthy Aging: A Systematic Review and Meta-Analysis
- Author
-
Di Bona D, Cristiano Caruso, Giuseppina Candore, Giulia Accardi, Claudia Virruso, Di Bona, D, Accardi, G, Virruso, C, Candore, G, and Caruso, C
- Subjects
Adult ,Aging ,media_common.quotation_subject ,Genome-wide association study ,Single-nucleotide polymorphism ,Biology ,Polymorphism, Single Nucleotide ,Young Adult ,Humans ,Genetic Predisposition to Disease ,Klotho Proteins ,Klotho ,Gene ,Aged ,Glucuronidase ,media_common ,Genetic association ,Longevity, Ageing, Klotho, Meta-Analysis ,Settore MED/04 - Patologia Generale ,Aged, 80 and over ,Genetics ,Infant, Newborn ,Longevity ,Infant ,Middle Aged ,Membrane protein ,Health ,Case-Control Studies ,Geriatrics and Gerontology ,Signal transduction ,Genome-Wide Association Study - Abstract
Today it is clearly evident that genetic background constitutes an integral part of aging and longevity. Many studies on long-lived people have been conducted emphasizing the role of certain genes in long life. Classic case-control studies, genome-wide association studies, and high-throughput sequencing have permitted identification of a variety of genetic variants seemingly associated with longevity. Over the years, aging research has focused on the insulin/insulin-like growth factor-1 (IGF-1) signaling pathway because of its evolutionarily conserved correlation with life-span extension in model animals. Indeed, many single-nucleotide polymorphisms (SNPs) associated with longevity were identified in genes encoding proteins that take part in this metabolic pathway. Closely related to this pathway is the Klotho gene. It encodes a type-I membrane protein expressed in two forms, membrane and secreted. The latter form suppresses oxidative stress and growth factor signaling and regulates ion channels and transporters. In particular, its over-expression seems to be able to suppress insulin/IGF-1 signaling extending life span. Thus, our aim was to assemble the results in the literature concerning the association between the functional variant of the Klotho "KL-VS" stretch, which contains six polymorphisms in linkage disequilibrium, and successful aging to quantify the possible effect of the variants. The results of our systematic review indicate that the Klotho KL-VS variant is associated with healthy aging.
- Published
- 2014
20. Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases
- Author
-
DI BONA, D., MONTALTO, G., CLEMENZA, L., BASCONE, F., ACCARDO, P., BELLAVIA, D., CRAXÌ, A., and BRAI, M.
- Published
- 1998
21. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review
- Author
-
Di Bona, D., primary, Plaia, A., additional, Leto‐Barone, M. S., additional, La Piana, S., additional, Macchia, L., additional, and Di Lorenzo, G., additional
- Published
- 2017
- Full Text
- View/download PDF
22. Hyperthermia Enhances CD95-Ligand Gene Expression in T Lymphocytes
- Author
-
Cippitelli, Marco, Fionda, Cinzia, Di Bona, D., Piccoli, Mario, Frati, Luigi, Santoni, Angela, and Equally contributed, °Cippitelli M. and Fionda C.
- Subjects
Hyperthermia ,Fas Ligand Protein ,Fever ,T-Lymphocytes ,T cell ,Blotting, Western ,Immunology ,Biology ,Lymphocyte Activation ,Transfection ,Fas ligand ,Jurkat Cells ,Transactivation ,Immune system ,Heat Shock Transcription Factors ,Lymphocyte homeostasis ,medicine ,Animals ,Humans ,Immunology and Allergy ,Cytotoxic T cell ,RNA, Messenger ,Promoter Regions, Genetic ,Transcription factor ,Protein Kinase C ,Membrane Glycoproteins ,NF-kappa B ,Blotting, Northern ,Cytotoxicity Tests, Immunologic ,medicine.disease ,Molecular biology ,Cell biology ,DNA-Binding Proteins ,Transcription Factor AP-1 ,medicine.anatomical_structure ,Gene Expression Regulation ,Mutation ,Transcription Factors - Abstract
Hyperthermia represents an interesting therapeutic strategy for the treatment of tumors. Moreover, it is able to regulate several aspects of the immune response. Fas (APO-1/CD95) and its ligand (FasL) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T cells, the Fas-Fas-L system regulates activation-induced cell death, is implicated in diseases in which lymphocyte homeostasis is compromised, and plays an important role during cytotoxic and regulatory actions mediated by these cells. In this study we describe the effect of hyperthermia on activation of the fas-L gene in T lymphocytes. We show that hyperthermic treatment enhances Fas-L-mediated cytotoxicity, fas-L mRNA expression, and fas-L promoter activity in activated T cell lines. Our data indicate that hyperthermia enhances the transcriptional activity of AP-1 and NF-κB in activated T cells, and this correlates with an increased expression/nuclear translocation of these transcription factors. Moreover, we found that heat shock factor-1 is a transactivator of fas-L promoter in activated T cells, and the overexpression of a dominant negative form of heat shock factor-1 may attenuate the effect of hyperthermia on fas-L promoter activity. Furthermore, overexpression of dominant negative mutants of protein kinase Cε (PKCε) and PKCθ partially inhibited the promoter activation and, more importantly, could significantly reduce the enhancement mediated by hyperthermia, indicating that modulation of PKC activity may play an important role in this regulation. These results add novel information on the immunomodulatory action of heat, in particular in the context of its possible use as an adjuvant therapeutic strategy to consider for the treatment of cancer.
- Published
- 2005
23. Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.
- Author
-
Nettis, E., Fabbrocini, G., Ortoncelli, M., Pellacani, G., Argenziano, G., Di Leo, E., Patruno, C., Stingeni, L., Foti, C., Rongioletti, F., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Calabrese, G., Di Bona, D., Nisticò, S.P., Hansel, K., and Romita, P.
- Subjects
ATOPIC dermatitis ,ECZEMA ,ADULTS - Abstract
Dear Editor, Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD).1 In this study, we aimed to assess the long-term effectiveness and safety of dupilumab in a real-world clinical setting. Primary effectiveness outcomes included the proportion of patients at week 52 achieving EASI improvements of 50%, 75% or 90% (EASI 50, EASI 75 or EASI 90). Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
24. Reply
- Author
-
Plaia A, Di Bona D, and Di Lorenzo G
- Subjects
business.industry ,Immunology ,Immunology and Allergy ,Medicine ,business - Published
- 2013
25. Le condizioni generali di trasporto
- Author
-
BEVILACQUA, Stefania, Di Bona, D., Tranquilli Leali De Angelis, R, Rosafio, E., Bevilacqua, S, and Di Bona, D.
- Subjects
Settore IUS/06 - Diritto Della Navigazione ,Condizioni di contratto, trasporto aereo - Published
- 2011
26. A Methodology for Graphical Modeling of Business Rules
- Author
-
Di Bona, D, Aiello, G, Tamburo, A, Alessi, M., LO RE, Giuseppe, Di Bona, D, Lo Re, G, Aiello, G, Tamburo, A, and Alessi, M
- Subjects
Settore ING-INF/05 - Sistemi Di Elaborazione Delle Informazioni ,Programming language ,Computer science ,Business rule ,Artifact-centric business process model ,Business process ,graphical modeling ,business rule ,BPMN ,methodology ,web graphical editor ,Business process modeling ,computer.software_genre ,Business domain ,rule engine ,BRMS ,Business rule management system ,Business Process Model and Notation ,Semantics of Business Vocabulary and Business Rules ,computer - Abstract
This work proposes a novel methodology based on the Business Process Modeling Notation (BPMN) standard capable of graphically modeling business rules. A set of new representation patterns allows business analysts to map processes described through BPMN into conditions and actions of business rules. Our approach exploits Domain Specific Language techniques in order to make the methodology independent from the programming language supported by the specific rule engine. Moreover, this work proposes a web graphical editor, instantiated on a specific sample scenario, where the selected rule engine is Drools, one of the most used open source products. The developed editor allows business analysts to graphically define business rules and to automatically generate executable code compliant with the selected rule engine. The case study and the resulting benchmarking show the effectiveness of the proposed methodology.
- Published
- 2011
27. IL-19 as putative biomarker for chronic rhinosinusitis with nasal polyps
- Author
-
Pace, E, Scafidi, V, Di Bona, D, Siena, L, Ballacchino, A, Chiappara, G, Bachert, C, Bousquet, J, Gjomarkaj, M., LA GRUTTA, Stefania, GALLINA, Salvatore, SPECIALE, Riccardo, Pace, E, Scafidi, V, Di Bona, D, Siena, L, La Grutta, S, Gallina, S, Speciale, R, Ballacchino, A, Chiappara, G, Bachert, C, Bousquet, J, and Gjomarkaj, M
- Subjects
Allergy, Biomarkers, Epithelial cells - Published
- 2010
28. Immune-inflammatory responses in successful and unsuccessful ageing
- Author
-
CANDORE, Giuseppina, BALISTRERI, Carmela Rita, BULATI, Matteo, COLONNA ROMANO, Giuseppina, FORTE, Giusi Irma, LIO, Domenico, LISTI', Florinda, PELLICANO', Mariavaleria, SCOLA, Letizia, VASTO, Sonya, CARUSO, Calogero, Di Bona, D, Candore, G, Balistreri, CR, Bulati, M, Colonna-Romano, G, Di Bona, D, Forte, GI, Lio, D, Listì, F, Pellicanò, M, Scola, L, Vasto, S, and Caruso, C
- Subjects
Inflammation ,Settore MED/04 - Patologia Generale ,Ageing ,Immunogenetics - Abstract
A dramatic increase in mean life span and life expectancy, coupled with a significant reduction in early mortality, has lead to a large increase in number of elderly people in modern societies. This demographic phenomenon has been paralleled by an epidemic of chronic diseases associated with advancing age. Both innate and instructive immunity are implicated in almost all age-related diseases. The modifications of the immune system in the elderly are evaluated as a deterioration of the immune system, the so-called immunosenescence, which is thought to be mostly the result of the declining effectiveness of T cells and it is responsible for the increased susceptibility of elderly to infectious diseases. In addition, a low-grade systemic inflammation characterizes ageing and inflammatory markers are significant predictors of mortality in old humans. This pro-inflammatory status of the elderly underlies biological mechanisms responsible for physical function decline and inflammatory age-related diseases are initiated or worsened by systemic inflammation.
- Published
- 2009
29. PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY
- Author
-
CAMMA', Calogero, DI MARCO, Vito, SANDONATO, Luigi, PARISI, Pietro, CABIBI, Daniela, PARDO, Salvatore, MONTALTO, Giuseppe, LATTERI, Mario, ORLANDO A, SCIARRINO E, VIRDONE R, CASARIL A, DI BONA D, ALIZZI S, NICOLI, CAMMA C, DI MARCO V, ORLANDO A, SANDONATO L, PARISI P, SCIARRINO E, VIRDONE R, CASARIL A, CABIBI D, PARDO S, DI BONA D, ALIZZI S, MONTALTO G, LATTERI MA, and NICOLI
- Abstract
PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION 8 RFTA) OF SMALL HEPATOCELLUALR CARCINOMA: A PROSPECTIVE STUDY Data: 2004 Dettaglio tipologia d'Ateneo: 3a - Articoli su riviste ISI (anche on line)
- Published
- 2004
30. Percutaneous radiofrequency therma ablation of small hepatocellular carcinoma: a prospective study
- Author
-
CAMMA', Calogero, DI MARCO, Vito, PARISI, Pietro, PARDO, Salvatore, MONTALTO, Giuseppe, LATTERI, Mario, CRAXI, Antonio, SANDONATO L, ORLANDO A, VIRDONE R, NICOLI N, CASARIL A, CABIBBI D, ALIZZI S, DI BONA D, CAMMA C, DI MARCO V, PARISI P, SANDONATO L, ORLANDO A, VIRDONE R, NICOLI N, CASARIL A, CABIBBI D, PARDO S, ALIZZI S, DI BONA D, MONTALTO G, LATTERI MA, and CRAXI A
- Published
- 2004
31. Immune-inflammatory responses and oxidative stress in Alzheimer' disease: therapeutic implications
- Author
-
DI BONA, D, Scapagnini, Giovanni, Candore, G, Castiglia, L, COLONNA ROMANO, G, Duro, G, Nuzzo, D, Iemolo, F, Lio, D, Pellicanò, M, Scafidi, V, Caruso, C, and Vasto, S.
- Published
- 2010
32. Energy recovery analysis of a CHP system based on a PEM fuel cell
- Author
-
Galloni, Enzo, DI BONA, D, Erme, G, and Jannelli, E.
- Published
- 2009
33. Performance Analysis of a Back-Up Power Generator Based on a Pemfc
- Author
-
Jannelli, Elio, Minutillo, Mariagiovanna, Perna, A, DI BONA, D, and Monsurro', M.
- Published
- 2007
34. KIR2 DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
- Author
-
Di Bona, D., Aiello, A., Colomba, C., Bilancia, M., Accardi, G., Rubino, R., Giannitrapani, L., Tuttolomondo, A., Cascio, A., Caiaffa, M. F., Rizzo, S., Di Lorenzo, G., Candore, G., Duro, G., Macchia, L., Montalto, G., and Caruso, C.
- Subjects
- *
IMMUNOGLOBULINS , *KILLER cells , *ANTIGENS , *VIRAL disease prevention , *HEPATITIS B virus - Abstract
Killer immunoglobulin-like receptors ( KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens ( HLA). KIR and HLA loci are highly polymorphic, and certain HLA- KIR combinations have been found to protect against viral infections. In this study, we analysed whether the KIR/ HLA repertoire may influence the course of hepatitis B virus ( HBV) infection. Fifty-seven subjects with chronic hepatitis B ( CHB), 44 subjects with resolved HBV infection and 60 healthy uninfected controls ( HC) were genotyped for KIR and their HLA ligands. The frequency of the HLA-A-Bw4 ligand group was higher in CHB (58%) than subjects with resolved infection (23%) (crude OR, 4.67; P<.001) and HC (10%) (crude OR, 12.38; P<.001). Similar results were obtained for the HLA-C2 ligand group, more frequent in CHB (84%), than subjects with resolved infection (70%) (crude OR, 2.24; P<.10) and HC (60%) (crude OR, 3.56; P<.01). Conversely, the frequency of KIR2 DL3 was lower in CHB (81%) than in subjects with resolved infection (98%) (crude OR, 0.10; P<.05). These results suggest a detrimental role of HLA-A-Bw4 and HLA-C2 groups, which are associated with the development of CHB, and a protective role of KIR2 DL3. A stepwise variable selection procedure, based on multiple logistic regression analysis, identified these three predictive variables as the most relevant, featuring high specificity (90.9%) and positive predictive value (87.5%) for the development of CHB. Our results suggest that a combination of KIR/ HLA gene/alleles is able to predict the outcome of HBV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
35. HLA and Killer Cell Immunoglobulin-like Receptors Influence the Natural Course of CMV Infection
- Author
-
Di Bona, D., primary, Scafidi, V., additional, Plaia, A., additional, Colomba, C., additional, Nuzzo, D., additional, Occhino, C., additional, Tuttolomondo, A., additional, Giammanco, G., additional, De Grazia, S., additional, Montalto, G., additional, Duro, G., additional, Cippitelli, M., additional, and Caruso, C., additional
- Published
- 2014
- Full Text
- View/download PDF
36. Trajectory Simulation and Optimization Methodolgy Applied to a SSTO Rocket Launcher Vehicle
- Author
-
D'Angelo, Salvatore, Minisci, E., DI BONA, D., Guerra, L., and Chiarelli, C.
- Published
- 2001
37. Optimization Methodology for Ascent Trajectories of Lifting Body Reusable Launcher
- Author
-
D'Angelo, Salvatore, Minisci, E, DI BONA, D, and Guerra, L.
- Published
- 2000
38. Optimization Methodology for the Climb Trajectory of a SSTO Lifting-Body Reusable Launcer
- Author
-
D'Angelo, Salvatore, Minisci, E., DI BONA, D., and Guerra, L.
- Published
- 1999
39. Guidance and Control for the Optimal Climb Trajectory of a SSTO Spaceplane
- Author
-
D'Angelo, Salvatore and DI BONA, D.
- Published
- 1996
40. Investigations on the behaviour of 2kW natural gas fuel processor
- Author
-
Di Bona, D., primary, Jannelli, Elio, additional, Minutillo, M., additional, and Perna, A., additional
- Published
- 2011
- Full Text
- View/download PDF
41. 234 Percutaneous radiofrequency thermal ablation (RFTA) of small hepatocellular carcinoma: A prospective study
- Author
-
Camma, C., primary, Di Marco, V., additional, Orlando, A., additional, Sandonato, L., additional, Parisi, P., additional, Sciarrino, E., additional, Virdone, R., additional, Casaril, A., additional, Cabibi, D., additional, Pardo, S., additional, Di Bona, D., additional, Alizzi, S., additional, Montalto, G., additional, Latteri, M.A., additional, Nicoli, N., additional, and Craxi, A., additional
- Published
- 2004
- Full Text
- View/download PDF
42. The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data
- Author
-
Camma, C., primary, Di Bona, D., additional, Schepis, F., additional, Heathcote, E.J., additional, Zeuzem, S., additional, Pockros, P.J., additional, Marcellin, P., additional, Alberti, A., additional, and Craxi, A., additional
- Published
- 2003
- Full Text
- View/download PDF
43. Chronic hepatitis C (CH-C) genotype 1: An independent, multicenter RCT comparing PEG-IFN ALFA-2B 12KD plus ribavirin (RBV) and IFN ALFA-2B plus (RBV) in naive patients
- Author
-
Bruno, S., primary, Camma, C., additional, Di Marco, V., additional, Rumi, M.G., additional, Vinci, M., additional, Camozzi, M., additional, Di Bona, D., additional, Mondelli, M., additional, Colombo, M., additional, Craxi, A., additional, and Pinzello, G., additional
- Published
- 2003
- Full Text
- View/download PDF
44. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.
- Author
-
Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C, Di Bona, Danilo, Rizzo, Claudia, Bonaventura, Giuseppe, Candore, Giuseppina, and Caruso, Calogero
- Abstract
It has been hypothesized that polymorphisms of interleukin (IL)-10 genes affect the risk of developing late onset Alzheimer's disease (AD). However, results of different studies are often inconsistent. Our aim was to investigate by meta-analysis the association of the common polymorphisms comprehensively defining the genetic variability of the IL-10 gene with AD risk. Fifteen studies investigating the association between IL-10 polymorphisms (-1082, -819, -592) and AD were found and analyzed. The model-free approach was applied to meta-analyze these case-control genetic association studies. Available data suggested an association between -1082 polymorphism and AD risk with a marginal statistical significance (GG versus
Ag/aa: pooled odds ratio [OR]: 0.82, 95% confidence interval CI: 0.65-1.02) and evidence of a moderate degree of between-study heterogeneity (χ2 = 27.13, d.f. = 13, p = 0.01, I2 = 52%). For the -819 and -592 polymorphisms, we did not find an association with AD, but significant between-study heterogeneity made genotype data pooling unacceptable. Analysis by IL-10 haplotype showed that the -1082G/-819C/-592C haplotype is associated with a lower risk of AD, although with a marginal statistical significance, probably due to the low number of studies included (GCC versus other genotypes: OR: 0.61, 95% CI: 0.32-1.15; I2: 85%). Current findings suggest a possible association between -1082 A > G polymorphism and the risk of developing AD; this effect is more evident in the oldest patients. The high degree of between-study heterogeneity, due to several underpowered studies and to other methodological problems of individual studies underlies the need for further methodologically adequate studies. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
45. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
- Author
-
Gabriella Fabbrocini, L Bonzano, Silvia Ferrucci, S Ribero, Simona Tavecchio, Giovanni Pellacani, Steven Paul Nisticò, C Detoraki, Franco Rongioletti, Cataldo Patruno, Paolo Romita, Eustachio Nettis, Viviana Piras, Michela Ortoncelli, M Carbonara, Giulia Calabrese, Danilo Di Bona, E. Di Leo, Luigi Macchia, Caterina Foti, G Argenziano, Maddalena Napolitano, Nettis, E, Ferrucci, S M, Ortoncelli, M, Pellacani, G, Foti, C, Di Leo, E, Patruno, C, Rongioletti, F, Argenziano, G, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Romita, P, Di Bona, D, Nisticò, S P, Piras, V, Calabrese, G, Detoraki, C, Carbonara, M, Fabbrocini, G, Nettis, E., Ferrucci, S. M., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Nistico, S. P., Piras, V., Calabrese, G., Detoraki, C., Carbonara, M., and Fabbrocini, G.
- Subjects
Adult ,medicine.medical_specialty ,Immunology ,Population ,Dupilumab ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Dermatitis, Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Retrospective Studie ,Interquartile range ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Eosinophilia ,Multicenter real-life study ,education ,Retrospective Studies ,Atopic dermatitis ,education.field_of_study ,business.industry ,Conjunctiviti ,Retrospective cohort study ,Dermatology Life Quality Index ,Immunoglobulin E ,Conjunctivitis ,Atopic dermatiti ,medicine.disease ,Clinical trial ,Treatment Outcome ,030228 respiratory system ,Multicentric real-life study ,medicine.symptom ,business ,Human - Abstract
BACKGROUND Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date. METHODS Adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at ten Italian academic centers, were included in the study. Physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index, DLQI) and serological markers [immunoglobulin (Ig) E and eosinophil count] after 16 weeks were analyzed. RESULTS We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median ± interquartile percentage change from baseline to 16 weeks of treatment in the EASI score was -87.5±22.0 (p
- Published
- 2022
46. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis
- Author
-
Giuseppe Valenti, Domenico Ciotta, Simona Pellegrino, Corrado Pelaia, Nunziata Ribecco, Nunzio Crimi, Girolamo Pelaia, Alessandro Vatrella, Alida Benfante, Angela Maria D'Uggento, Giulia Scioscia, Danilo Di Bona, Luigi Macchia, Maria Filomena Caiaffa, Giovanna Elisiana Carpagnano, Claudia Crimi, Cecilia Calabrese, Raffaele Campisi, Nicola Scichilone, Giuseppe Spadaro, Maria D'Amato, Di Bona D., Crimi C., D'Uggento A.M., Benfante A., Caiaffa M.F., Calabrese C., Campisi R., Carpagnano G.E., Ciotta D., D'Amato M., Pelaia C., Pelaia G., Pellegrino S., Scichilone N., Scioscia G., Ribecco N., Spadaro G., Valenti G., Vatrella A., Crimi N., Macchia L., Di Bona, D., Crimi, C., D'Uggento, A. M., Benfante, A., Caiaffa, M. F., Calabrese, C., Campisi, R., Carpagnano, G. E., Ciotta, D., D'Amato, M., Pelaia, C., Pelaia, G., Pellegrino, S., Scichilone, N., Scioscia, G., Ribecco, N., Spadaro, G., Valenti, G., Vatrella, A., Crimi, N., Macchia, L., Di Bona, Danilo, Crimi, Claudia, Maria D'Uggento, Angela, Benfante, Alida, Filomena Caiaffa, Maria, Calabrese, Cecilia, Campisi, Raffaele, Elisiana Carpagnano, Giovanna, Ciotta, Domenico, D'Amato, Maria, Pelaia, Corrado, Pelaia, Girolamo, Pellegrino, Simona, Scichilone, Nicola, Scioscia, Giulia, Ribecco, Nunziata, Spadaro, Giuseppe, Valenti, Giuseppe, Vatrella, Alessandro, Crimi, Nunzio, and Macchia, Luigi
- Subjects
medicine.medical_specialty ,Exacerbation ,biologicals, monoclonal antibodies, observational studies, precision medicine, real-life ,precision medicine ,Immunology ,Disease ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Immunoglobulin E ,Antibodies, Monoclonal, Humanized ,observational studie ,chemistry.chemical_compound ,Internal medicine ,medicine ,Immunology and Allergy ,Cluster Analysis ,Humans ,Anti-Asthmatic Agents ,real-life ,observational studies ,monoclonal antibodie ,Response rate (survey) ,Bronchiectasis ,biology ,business.industry ,medicine.disease ,Benralizumab ,Phenotype ,Asthma ,Eosinophils ,chemistry ,biologicals ,biology.protein ,Disease Progression ,Biomarker (medicine) ,monoclonal antibodies ,business ,biological - Abstract
Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensitization status, blood eosinophil count, IgE levels, FEV1% predicted, nasal polyposis, bronchiectasis). Results: Four clusters were identified: Clusters 2 and 3 included patients with high levels of both IgE and eosinophils (type-2 biomarkers high), whereas Clusters 1 and 4 included patients with only one type-2 biomarker at a high level: IgE in Cluster 1 and eosinophils in Cluster 4. Clusters 2 and 3 (both type-2 biomarkers high) showed the highest response rate to benralizumab in terms of elimination of exacerbations (79% and 80% respectively) compared to Clusters 1 and 4 (52% and 60% respectively). When super-response (the absence of exacerbation without oral corticosteroid use) was assessed, Cluster 2, including patients with more preserved lung function than the other clusters, but comparable exacerbation rate, oral corticosteroid use and symptom severity, was the most responsive cluster (87.5% of patients). Conclusions: Our cluster analysis identified benralizumab differential response sub-phenotypes in SEA, with the potential of improving disease treatment and precision management.
- Published
- 2022
47. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
- Author
-
Silvia Ferrucci, Simona Tavecchio, L Bonzano, Luigi Macchia, Giulia Calabrese, Maddalena Napolitano, Steven Paul Nisticò, Caterina Foti, Aikaterini Detoraki, Katharina Hansel, Giuseppe Argenziano, Giovanni Pellacani, Paolo Romita, Michela Ortoncelli, Franco Rongioletti, Luca Stingeni, E. Di Leo, Gabriella Fabbrocini, Simone Ribero, M Carbonara, Cataldo Patruno, Eustachio Nettis, Viviana Piras, Danilo Di Bona, Nettis, E, Fabbrocini, G, Ortoncelli, M, Pellacani, G, Argenziano, G, Di Leo, E, Patruno, C, Stingeni, L, Foti, C, Rongioletti, F, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Calabrese, G, Di Bona, D, Nisticò, S P, Hansel, K, Romita, P, Piras, V, Carbonara, M, Detoraki, A, Ferrucci, S M, Nettis, E., Fabbrocini, G., Ortoncelli, M., Pellacani, G., Argenziano, G., Di Leo, E., Patruno, C., Stingeni, L., Foti, C., Rongioletti, F., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Calabrese, G., Di Bona, D., Nistico, S. P., Hansel, K., Romita, P., Piras, V., Carbonara, M., Detoraki, A., and Ferrucci, S. M.
- Subjects
Adult ,medicine.medical_specialty ,Adult patients ,business.industry ,Eczema ,Interleukin ,Dermatology ,Atopic dermatitis ,medicine.disease ,Antibodies, Monoclonal, Humanized ,Dupilumab ,Dermatitis, Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Monoclonal ,Medicine ,Humans ,business - Abstract
Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.
- Published
- 2021
48. Severe asthma: One disease and multiple definitions
- Author
-
Maria Teresa Costantino, Luigi Macchia, Angelo Corsico, Andrea Airoldi, Carla Galeone, Zappa Maria Cristina, Paolo Tarsia, Foschino Barbaro Maria Pia, Silvia Ruggeri, Pierluigi Paggiaro, Lorenzo Cosmi, A. Farsi, Vitina Maria Anna Carriero, Arianna Bassi, Francesca Bertolini, Giovanni Passalacqua, Fulvia Chieco Bianchi, Carlo Lombardi, Salvatore Lo Cicero, Giovanni Rolla, Carmen Durante, Rocco Rinaldo, Elena Parazzini, Arianna Aruanno, Maria Rita Marchi, Chiara Folli, Alessandra Arcolaci, Carlo Pasculli, Fabio Luigi Massimo Ricciardolo, Vittorio Viviano, Alvise Berti, Stefano Del Giacco, Andrea Manfredi, Roberta Barlassina, Agata Valentina Frazzetto, Pierachille Santus, Luisa Brussino, Anna del Colle, Marco Bonavia, Dina Visca, Nicola Scichilone, Patrizia Pignatti, Enrico Heffler, Francesca Racca, Giuseppe Santini, Nucera Eleonora, Giovanna Elisiana Carpagnano, Linda Di Pietro, Stefano Centanni, Maria Elisabetta Conte, Vincenzo Patella, Monna Rita Yacoub, Diego Bagnasco, Nunzio Crimi, Anna Maria Riccio, Stefania Isola, Margherita Deidda, Gabriella Guarnieri, Giuseppe Guida, Elena Minenna, Manuela Latorre, Gianna Camiciottoli, Maria Vittoria Verrillo, Luca Richeldi, Marcello Montagni, Francesca Cicero, Maria Filomena Caiaffa, Antonio Spanevello, Cecilia Calabrese, Carlo Barbetta, Elisabetta Favero, Gianenrico Senna, Giuliana Amato, Amelia Grosso, Federica Vita, Francesco Blasi, Luisa Ricciardi, Carola Condoluci, Massimo Triggiani, Enrico Maggi, Mariacarmela Di Proietto, Giulia Carli, Roberta Parente, Eleonora Savi, Chiara Roncallo, Paolo Montuschi, Luciana D'Elia, Francesco Mazza, Simona D’Alo, Patrizia Ruggiero, Francesca Puggioni, Matteo Bonini, Simone Luraschi, Francesco Menzella, Leonello Fuso, Marco Caminati, Martina Flora, Mariachiara Braschi, Cristiano Caruso, Angela Rizzi, Sandra Iannacone, Rikki Frank Canevari, Andrea Vianello, D’Amato Maria, Manlio Milanese, Stefania Colantuono, Giorgio Walter Canonica, Giulia Scioscia, Laura Pini, Elisa Testino, Erminia Ridolo, Joyce Rolo, Elisa Turchet, Pelaia Gerolamo, Danilo Di Bona, Laura De Ferrari, Francesca Cherubino, Alice D’Adda, Marianna Lilli, Giuseppe Spadaro, Stefano Pucci, Caterina Detoraki, Chiara Allegrini, Bagnasco, D., Paggiaro, P., Latorre, M., Folli, C., Testino, E., Bassi, A., Milanese, M., Heffler, E., Manfredi, A., Riccio, A. M., De Ferrari, L., Blasi, F., Canevari, R. F., Canonica, G. W., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, G. E., Colle, A. D., Scioscia, G., Gerolamo, P., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Lombardi, C., Spadaro, G., Detoraki, C., Menzella, F., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, A., Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Rolla, G., Brussino, L., Frazzetto, A. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, F., Santus, P., Barlassina, R., Airoldi, A., Guida, G., Eleonora, N., Aruanno, A., Rizzi, A., Caruso, C., Colantuono, S., Senna, G., Caminati, M., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, C., Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, L., Condoluci, C., Fuso, L., Bonini, M., Farsi, A., Carli, G., Montuschi, P., Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, S., Bagnasco D., Paggiaro P., Latorre M., Folli C., Testino E., Bassi A., Milanese M., Heffler E., Manfredi A., Riccio A.M., De Ferrari L., Blasi F., Canevari R.F., Canonica G.W., Passalacqua G., Guarnieri G., Patella V., Maria Pia F.B., Carpagnano G.E., Colle A.D., Scioscia G., Gerolamo P., Puggioni F., Racca F., Favero E., Iannacone S., Savi E., Montagni M., Camiciottoli G., Allegrini C., Lombardi C., Spadaro G., Detoraki C., Menzella F., Galeone C., Ruggiero P., Yacoub M.R., Berti A., Scichilone N., Durante C., Costantino M.T., Roncallo C., Braschi M., D'Adda A., Ridolo E., Triggiani M., Parente R., Maria D.A., Verrillo M.V., Rolla G., Brussino L., Frazzetto A.V., Cristina Z.M., Lilli M., Crimi N., Bonavia M., Corsico A.G., Grosso A., Del Giacco S., Deidda M., Ricciardi L., Isola S., Cicero F., Amato G., Vita F., Spanevello A., Pignatti P., Cherubino F., Visca D., Massimo Ricciardolo F.L., Anna Carriero V.M., Bertolini F., Santus P., Barlassina R., Airoldi A., Guida G., Eleonora N., Aruanno A., Rizzi A., Caruso C., Colantuono S., Senna G., Caminati M., Arcolaci A., Vianello A., Bianchi F.C., Marchi M.R., Centanni S., Luraschi S., Ruggeri S., Rinaldo R., Parazzini E., Calabrese C., Flora M., Cosmi L., Di Pietro L., Maggi E., Pini L., Macchia L., Di Bona D., Richeldi L., Condoluci C., Fuso L., Bonini M., Farsi A., Carli G., Montuschi P., Santini G., Conte M.E., Turchet E., Barbetta C., Mazza F., D'Alo S., Pucci S., Caiaffa M.F., Minenna E., D'Elia L., Pasculli C., Viviano V., Tarsia P., Rolo J., Di Proietto M., Lo Cicero S., Bagnasco, D, Paggiaro, P, Latorre, M, Folli, C, Testino, E, Bassi, A, Milanese, M, Heffler, E, Manfredi, A, Riccio, A, De Ferrari, L, Blasi, F, Frank Canevari, R, Canonica, G, Passalacqua, G, Guarnieri, G, Patella, V, Foschino Barbaro, M, Carpagnano, G, del Colle, A, Scioscia, G, Gerolamo, P, Puggioni, F, Racca, F, Favero, E, Iannacone, S, Savi, E, Montagni, M, Camiciottoli, G, Allegrini, C, Lombardi, C, Spadaro, G, Detoraki, C, Menzella, F, Galeone, C, Ruggiero, P, Yacoub, R, Verrillo, M, Rolla, G, and Lo Cicero, S
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Severe asthma ,Immunology ,Nice ,Disease ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,Article ,Pulmonary function testing ,Internal medicine ,Biological treatment ,Classification ,Definition ,medicine ,Immunology and Allergy ,Respiratory function ,computer.programming_language ,Biological therapies ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,RC581-607 ,Severe asthma, Classification, Definition, Biological treatment ,Biological treatment, Classification, Definition, Severe asthma ,Immunologic diseases. Allergy ,business ,computer - Abstract
Introduction There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients. Methods Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED, NICE, WHO, ATS/ERS, GINA, ENFUMOSA, and TENOR. Results 540 patients, were extracted from the SANI database. We observed that 462 (86%) met the ATS/ERS criteria as well as the GINA criteria, 259 (48%) the U-Biopred, 222 (41%) the NICE, 125 (23%) the WHO, 313 (58%) the Enfumosa, and 251 (46%) the TENOR criteria. The mean eosinophil value were similar in the ATS/ERS, U-Biopred, and Enfumosa (528, 532 and 516 cells/mcl), higher in WHO and Tenor (567 and 570 cells/mcl) and much higher in the NICE classification (624 cells/mcl). Lung function tests resulted similarly in all groups, with WHO (67%) and ATS/ERS-GINA (73%), respectively, showing the lower and upper mean FEV1 values. Conclusions The present observations clearly evidence the heterogeneity in the distribution of patients when different definitions of severe asthma are used. However, the recent definition of severe asthma, provided by the GINA document, is similar to that indicated in 2014 by ATS/ERS, allowing mirror reclassification of the patients examined. This lack of homogeneity could complicate the access to biological therapies. The definition provided by the GINA document, which reflects what suggested by ATS/ERS, could partially overcome the problem.
- Published
- 2021
49. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
- Author
-
Diego Bagnasco, Massimiliano Povero, Lorenzo Pradelli, Luisa Brussino, Giovanni Rolla, Marco Caminati, Francesco Menzella, Enrico Heffler, Giorgio Walter Canonica, Pierluigi Paggiaro, Gianenrico Senna, Manlio Milanese, Carlo Lombardi, Caterina Bucca, Andrea Manfredi, Rikki Frank Canevari, Giovanni Passalacqua, Gabriella Guarnieri, Vincenzo Patella, Foschino Barbaro Maria Pia, Elisiana Carpagnano, Anna del Colle, Giulia Scioscia, Pelaia Gerolamo, Manuela Latorre, Francesca Puggioni, Francesca Racca, Elisabetta Favero, Sandra Iannacone, Eleonora Savi, Marcello Montagni, Gianna Camiciottoli, Chiara Allegrini, Giuseppe Spadaro, Caterina Detoraki, Carla Galeone, Patrizia Ruggiero, Monna Rita Yacoub, Alvise Berti, Gisella Colombo, Nicola Scichilone, Carmen Durante, Maria Teresa Costantino, Chiara Roncallo, Mariachiara Braschi, Francesco Blasi, Alice D'Adda, Erminia Ridolo, Massimo Triggiani, Roberta Parente, D'Amato Maria, Maria Vittoria Verrillo, Zappa Maria Cristina, Marianna Lilli, Nunzio Crimi, Marco Bonavia, Angelo Guido Corsico, Amelia Grosso, Stefano Del Giacco, Margherita Deidda, Luisa Ricciardi, Stefania Isola, Francesca Cicero, Giuliana Amato, Federica Vita, Antonio Spanevello, Patrizia Pignatti, Francesca Cherubino, Dina Visca, Eleonora Aletti, Fabio Luigi Massimo Ricciardolo, Vitina Maria Anna Carriero, Francesca Bertolini, Pierachille Santus, Roberta Barlassina, Andrea Airoldi, Giuseppe Guida, Nucera Eleonora, Arianna Aruanno, Angela Rizzi, Cristiano Caruso, Stefania Colantuono, Alessandra Arcolaci, Andrea Vianello, Fulvia Chieco Bianchi, Maria Rita Marchi, Stefano Centanni, Simone Luraschi, Silvia Ruggeri, Rocco Rinaldo, Elena Parazzini, Cecilia Calabrese, Martina Flora, Lorenzo Cosmi, Linda Di Pietro, Enrico Maggi, Laura Pini, Luigi Macchia, Danilo Di Bona, Luca Richeldi, Carola Condoluci, Leonello Fuso, Matteo Bonini, Alessandro Farsi, Giulia Carli, Paolo Montuschi, Giuseppe Santini, Maria Elisabetta Conte, Elisa Turchet, Carlo Barbetta, Francesco Mazza, Simona D'Alo, Stefano Pucci, Maria Filomena Caiaffa, Elena Minenna, Luciana D'Elia, Carlo Pasculli, Vittorio Viviano, Paolo Tarsia, Joyce Rolo, Mariacarmela Di Proietto, Salvatore Lo Cicero, Bagnasco, D., Povero, M., Pradelli, L., Brussino, L., Rolla, G., Caminati, M., Menzella, F., Heffler, E., Canonica, G. W., Paggiaro, P., Senna, G., Milanese, M., Lombardi, C., Bucca, C., Manfredi, A., Canevari, R. F., Passalacqua, G., Guarnieri, G., Patella, V., Maria Pia, F. B., Carpagnano, E., Colle, A. D., Scioscia, G., Gerolamo, P., Latorre, M., Puggioni, F., Racca, F., Favero, E., Iannacone, S., Savi, E., Montagni, M., Camiciottoli, G., Allegrini, C., Spadaro, G., Detoraki, C., Galeone, C., Ruggiero, P., Yacoub, M. R., Berti, A., Colombo, G., Scichilone, N., Durante, C., Costantino, M. T., Roncallo, C., Braschi, M., Blasi, F., D'Adda, A., Ridolo, E., Triggiani, M., Parente, R., Maria, D. A., Verrillo, M. V., Cristina, Z. M., Lilli, M., Crimi, N., Bonavia, M., Corsico, A. G., Grosso, A., Del Giacco, S., Deidda, M., Ricciardi, L., Isola, S., Cicero, F., Amato, G., Vita, F., Spanevello, A., Pignatti, P., Cherubino, F., Visca, D., Aletti, E., Massimo Ricciardolo, F. L., Anna Carriero, V. M., Bertolini, F., Santus, P., Barlassina, R., Airoldi, A., Guida, G., Eleonora, N., Aruanno, A., Rizzi, A., Caruso, C., Colantuono, S., Arcolaci, A., Vianello, A., Bianchi, F. C., Marchi, M. R., Centanni, S., Luraschi, S., Ruggeri, S., Rinaldo, R., Parazzini, E., Calabrese, C., Flora, M., Cosmi, L., Di Pietro, L., Maggi, E., Pini, L., Macchia, L., Di Bona, D., Richeldi, L., Condoluci, C., Fuso, L., Bonini, M., Farsi, A., Carli, G., Montuschi, P., Santini, G., Conte, M. E., Turchet, E., Barbetta, C., Mazza, F., D'Alo, S., Pucci, S., Caiaffa, M. F., Minenna, E., D'Elia, L., Pasculli, C., Viviano, V., Tarsia, P., Rolo, J., Di Proietto, M., Lo Cicero, S., Bagnasco, Diego, Povero, Massimiliano, Pradelli, Lorenzo, Brussino, Luisa, Rolla, Giovanni, Caminati, Marco, Menzella, Francesco, Heffler, Enrico, Canonica, Giorgio Walter, Paggiaro, Pierluigi, Senna, Gianenrico, Milanese, Manlio, Lombardi, Carlo, Bucca, Caterina, Manfredi, Andrea, Canevari, Rikki Frank, Passalacqua, Giovanni, Guarnieri, Gabriella, Patella, Vincenzo, Foschino Barbaro, Maria Pia, Carpagnano, Elisiana, D' Amato, Maria, Verrillo, Mariavittoria, Zappa, Maria Cristina, Lo Cicero, Salvatore, Di Proietto, Maria Carmela, Walter Canonica, Giorgio, Frank Canevari, Rikki, Spadaro, Giuseppe, Bagnasco D., Povero M., Pradelli L., Brussino L., Rolla G., Caminati M., Menzella F., Heffler E., Canonica G.W., Paggiaro P., Senna G., Milanese M., Lombardi C., Bucca C., Manfredi A., Canevari R.F., Passalacqua G., Guarnieri G., Patella V., Maria Pia F.B., Carpagnano E., Colle A.D., Scioscia G., Gerolamo P., Latorre M., Puggioni F., Racca F., Favero E., Iannacone S., Savi E., Montagni M., Camiciottoli G., Allegrini C., Spadaro G., Detoraki C., Galeone C., Ruggiero P., Yacoub M.R., Berti A., Colombo G., Scichilone N., Durante C., Costantino M.T., Roncallo C., Braschi M., Blasi F., D'Adda A., Ridolo E., Triggiani M., Parente R., Maria D.A., Verrillo M.V., Cristina Z.M., Lilli M., Crimi N., Bonavia M., Corsico A.G., Grosso A., Del Giacco S., Deidda M., Ricciardi L., Isola S., Cicero F., Amato G., Vita F., Spanevello A., Pignatti P., Cherubino F., Visca D., Aletti E., Massimo Ricciardolo F.L., Anna Carriero V.M., Bertolini F., Santus P., Barlassina R., Airoldi A., Guida G., Eleonora N., Aruanno A., Rizzi A., Caruso C., Colantuono S., Arcolaci A., Vianello A., Bianchi F.C., Marchi M.R., Centanni S., Luraschi S., Ruggeri S., Rinaldo R., Parazzini E., Calabrese C., Flora M., Cosmi L., Di Pietro L., Maggi E., Pini L., Macchia L., Di Bona D., Richeldi L., Condoluci C., Fuso L., Bonini M., Farsi A., Carli G., Montuschi P., Santini G., Conte M.E., Turchet E., Barbetta C., Mazza F., D'Alo S., Pucci S., Caiaffa M.F., Minenna E., D'Elia L., Pasculli C., Viviano V., Tarsia P., Rolo J., Di Proietto M., and Lo Cicero S.
- Subjects
OR, Odds Ratio ,Pediatrics ,Severe asthma ,Exacerbation ,Anti IL-5 ,Comorbidities ,Mepolizumab ,OCS ,Pharmacoeconomics ,gastroesophageal reflux disease ,Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO ,ICS, inhaled corticosteroid ,Rate ratio ,OCS, Oral Corticosteroids ,law.invention ,LAMA, long acting muscarinic antagonist ,0302 clinical medicine ,Randomized controlled trial ,fractional nitric oxide ,Interquartile range ,law ,long acting beta 2 agonist ,Odds Ratio ,Immunology and Allergy ,RR, Rate Ratio ,030223 otorhinolaryngology ,Pharmacoeconomic ,LOS, Length of stay ,LOS ,IQR ,LAMA ,MEP, Mepolizumab ,OR ,CI ,SD, Standard Deviation ,MEP ,ACT, Asthma Control Test ,Comorbiditie ,CI, Confidence Intervals ,medicine.drug ,lcsh:Immunologic diseases. Allergy ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,interquartile range ,long acting muscarinic antagonist ,Immunology ,LABA ,LABA, long acting beta 2 agonist ,Comorbidities, Mepolizumab, OCS, Pharmacoeconomics, Severe asthma, Anti IL-5 ,RR ,Article ,Rate Ratio ,chronic obstructive pulmonary disease ,03 medical and health sciences ,OCS, Oral Corticosteroid ,Asthma Control Test ,Confidence Intervals ,FeNO, fractional nitric oxide ,RCTs, Randomized Controlled Trial ,medicine ,COPD ,GERD, gastroesophageal reflux disease ,FeNO ,IQR, interquartile range ,SD ,Asthma ,RCTs ,Oral Corticosteroids ,business.industry ,GERD ,medicine.disease ,ICS, inhaled corticosteroids ,ACT ,Comorbidity ,Randomized Controlled Trials ,CI, Confidence Interval ,RCTs, Randomized Controlled Trials ,COPD, chronic obstructive pulmonary disease ,030228 respiratory system ,ICS ,Standard Deviation ,Length of stay ,inhaled corticosteroids ,lcsh:RC581-607 ,business - Abstract
Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of working days lost due to the disease. The primary objective was to compare the annual total cost per patient pre- and post-MEP. Secondary outcomes included rates of exacerbations and number of OCS-dependent patients. Results 106 patients were enrolled in the study: 46 male, median age 58 years. Mean annual cost pre- and post-MEP (cost of biologic excluded) was €3996 and €1,527, respectively. Total savings due to MEP resulted in €2469 (95%CI 1945–2993), 62% due to exacerbations reduction and 33% due to productivity increase. Such savings could fund about 22% of the total cost of MEP for one year. The introduction of MEP induced a clinical benefit by reducing both OCS-dependent patients (OR = 0.12, 95%CI 0.06–0.23) and exacerbation rate (RR = 0.19, 95%CI 0.15–0.24). Conclusions Patients with severe eosinophilic asthma experienced a clinical benefit in asthma control adding MEP to standard therapy. Biologic therapy can be, partially, funded by the savings produced by patients’ improvement.
- Published
- 2021
50. A multicentric study on prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis
- Author
-
Cataldo Patruno, Silvia Ferrucci, L Bonzano, Eustachio Nettis, Viviana Piras, Giulia Calabrese, Gabriella Fabbrocini, Maddalena Napolitano, M Carbonara, C Detoraki, Caterina Foti, Simona Tavecchio, Franco Rongioletti, Simone Ribero, G Argenziano, Luigi Macchia, Danilo Di Bona, E. Di Leo, Luigi Bennardo, Giovanni Pellacani, Michela Ortoncelli, Paolo Romita, Nettis, E, Ortoncelli, M, Pellacani, G, Foti, C, Di Leo, E, Patruno, C, Rongioletti, F, Argenziano, G, Ferrucci, S M, Macchia, L, Napolitano, M, Ribero, S, Bonzano, L, Romita, P, Di Bona, D, Bennardo, L, Piras, V, Calabrese, G, Tavecchio, S, Detoraki, C, Carbonara, M, Fabbrocini, G, Nettis, E., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Ferrucci, S. M., Macchia, L., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Bennardo, L., Piras, V., Calabrese, G., Tavecchio, S., Detoraki, C., Carbonara, M., and Fabbrocini, G.
- Subjects
Adult ,medicine.medical_specialty ,Immunology ,Atopic dermatitis ,Clinical patterns ,Clinical phenotypes ,Dupilumab ,MEDLINE ,Dermatitis, Atopic ,Clinical phenotype ,medicine ,Prevalence ,Immunology and Allergy ,Humans ,Public Health Surveillance ,Adult atopic dermatitis ,business.industry ,medicine.disease ,Atopic dermatiti ,Phenotype ,Dermatology ,Multicenter study ,Clinical pattern ,business - Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.